StoxPark Medi World Limited
NSE: PARKHOSPS · Healthcare
Ask the data
Instant answers about Park Medi World Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 1,679 |
| EBITDA | 444 |
| Operating margin | 26.5% |
| Interest | 59 |
| Depreciation | 62 |
| Profit before tax | 355 |
| Tax | 81 |
| Net profit | 258 |
| EPS ₹ | 6.87 |
| Operating cash flow | 329 |
| Capex | 120 |
| Dividend paid | 0 |
| Total assets | 2,813 |
| Equity | 2,022 |
Quarterly performance
last 3 quarters · ₹ crore| DEC '25 | MAR '26 | JUN '26 | |
|---|---|---|---|
| Revenue | 410 | 460 | 476 |
| Operating profit | 99 | 127 | 126 |
| Operating margin | 24.2% | 27.7% | 26.5% |
| Other income | 9 | 8 | 8 |
| Interest | 15 | 14 | 10 |
| Depreciation | 15 | 18 | 19 |
| Profit before tax | 78 | 103 | 105 |
| Tax | 25 | 27 | 16 |
| Net profit | 51 | 71 | 83 |
| EPS ₹ | 1.35 | 1.78 | 2.05 |
Returns & margins
trailing-twelve-month, per quarterNot filed yet.
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '26 | |
|---|---|
| Share capital | 86 |
| Other equity / reserves | 1,936 |
| Total equity | 2,022 |
| Borrowings | 228 |
| Current liabilities | 529 |
| Non-current liabilities | 180 |
| Total assets | 2,813 |
| Property, plant & equipment | 788 |
| Capital work-in-progress | 123 |
| Investments | 0 |
| Inventories | 3 |
| Receivables | 593 |
| Cash & equivalents | 237 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | 329 |
| Cash from investing | -333 |
| Cash from financing | 121 |
| Capex | 120 |
| Free cash flow | 209 |
| Dividends paid | 0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Park Medi World Limited | 10,858 | 251.39 | — | 5.37 | — |
StoxGud checklist: Neutral setup · 4/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Park Medi World Limited?
Park Medi World Limited (PARKHOSPS) closed at ₹251.39 on NSE on 06 Nov 2026.
What is the market cap of Park Medi World Limited?
₹10,858 crore at the latest close.
How fast is Park Medi World Limited growing?
Not enough filed history yet to measure Park Medi World Limited's growth.
How profitable is Park Medi World Limited?
Profitability ratios for Park Medi World Limited aren't available yet.
How much debt does Park Medi World Limited have?
Park Medi World Limited is lightly geared: debt to equity is 0.11 with borrowings of ₹228 cr against cash of ₹237 cr (balance sheet of 2026-03-31).
Financials parsed from Park Medi World Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from DEC '25, annual from FY26, balance sheet from Mar '26. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.